Literature DB >> 27450926

An LC-MS/MS method for rapid and sensitive high-throughput simultaneous determination of various protein kinase inhibitors in human plasma.

Ali S Abdelhameed1, Mohamed W Attwa1, Adnan A Kadi1.   

Abstract

A reliable, high-throughput and sensitive LC-MS/MS procedure was developed and validated for the determination of five tyrosine kinase inhibitors in human plasma. Following their extraction from human plasma, samples were eluted on a RP Luna®-PFP 100 Å column using a mobile phase system composed of acetonitrile and 0.01 m ammonium formate in water (pH ~4.1) with a ratio of (50:50, v/v) flowing at 0.3 mL min-1 . The mass spectrometer was operating with electrospray ionization in the positive ion multiple reaction monitoring mode. The proposed methodology resulted in linear calibration plots with correlation coefficients values of r2  = 0.9995-0.9999 from concentration ranges of 2.5-100 ng mL-1 for imatinib, 5.0-100 ng mL-1 for sorafenib, tofacitinib and afatinib, and 1.0-100 ng mL-1 for cabozantinib. The procedure was validated in terms of its specificity, limit of detection (0.32-1.71 ng mL-1 ), lower limit of quantification (0.97-5.07 ng mL-1 ), intra- and inter assay accuracy (-3.83 to +2.40%) and precision (<3.37%), matrix effect and recovery and stability. Our results demonstrated that the proposed method is highly reliable for routine quantification of the investigated tyrosine kinase inhibitors in human plasma and can be efficiently applied in the rapid and sensitive analysis of their clinical samples.
Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  LC-MS/MS; human plasma; tyrosine kinase inhibitors

Mesh:

Substances:

Year:  2016        PMID: 27450926     DOI: 10.1002/bmc.3793

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  14 in total

1.  LC-MS/MS Estimation of the Anti-Cancer Agent Tandutinib Levels in Human Liver Microsomes: Metabolic Stability Evaluation Assay.

Authors:  Mohamed W Attwa; Ali S Abdelhameed; Nasser S Al-Shakliah; Adnan A Kadi
Journal:  Drug Des Devel Ther       Date:  2020-10-23       Impact factor: 4.162

2.  LC-MS/MS Estimation of Rociletinib Levels in Human Liver Microsomes: Application to Metabolic Stability Estimation.

Authors:  Mohamed W Attwa; Ali S Abdelhameed; Adnan A Kadi
Journal:  Drug Des Devel Ther       Date:  2021-09-15       Impact factor: 4.162

3.  Simultaneous Determination of Two Tyrosine Kinase Inhibitors in Tablets by HPLC-MS analysis.

Authors:  Daniela Maria Croitoru; Costel-Valentin Manda; Johny Neamţu; Andrei Biţă; Octavian Croitoru; Sofia Teodora Stancu; Simona-Daniela Neamţu
Journal:  Curr Health Sci J       Date:  2022-03-31

4.  Metabolic Stability Assessment of Larotrectinib Using Liquid Chromatography Tandem Mass Spectrometry.

Authors:  Mohamed W Attwa; Adnan A Kadi; Hany W Darwish
Journal:  Drug Des Devel Ther       Date:  2020-01-10       Impact factor: 4.162

5.  An Accurate and Effective Method for Measuring Osimertinib by UPLC-TOF-MS and Its Pharmacokinetic Study in Rats.

Authors:  Song-Tao Dong; Ying Li; Hao-Tian Yang; Yin Wu; Ya-Jing Li; Cong-Yang Ding; Lu Meng; Zhan-Jun Dong; Yuan Zhang
Journal:  Molecules       Date:  2018-11-06       Impact factor: 4.411

6.  Validated LC-MS/MS assay for quantification of the newly approved tyrosine kinase inhibitor, dacomitinib, and application to investigating its metabolic stability.

Authors:  Ali S Abdelhameed; Adnan A Kadi; Mohamed W Attwa; Haitham AlRabiah
Journal:  PLoS One       Date:  2019-04-04       Impact factor: 3.240

7.  Development of two different formats of heterogeneous fluorescence immunoassay for bioanalysis of afatinib by employing fluorescence plate reader and KinExA 3200 immunosensor.

Authors:  Ibrahim A Darwish; Haitham AlRabiah; Mohammed A Hamidaddin
Journal:  Sci Rep       Date:  2019-10-14       Impact factor: 4.379

8.  Liquid chromatography-tandem mass spectrometry metabolic profiling of nazartinib reveals the formation of unexpected reactive metabolites.

Authors:  Ali S Abdelhameed; Mohamed W Attwa; Adnan A Kadi
Journal:  R Soc Open Sci       Date:  2019-08-14       Impact factor: 2.963

9.  Quantitation of Cabozantinib in Human Plasma by LC-MS/MS.

Authors:  Reyna Jones; Julianne Holleran; Robert A Parise; Michelle A Rudek; Jennifer Chan; Yujia Wen; Joga Gobburu; Lionel D Lewis; Jan H Beumer
Journal:  J Chromatogr Sci       Date:  2022-03-23       Impact factor: 1.555

10.  Preclinical testing of 5-amino-1-((1R,2S,3S,4R)-2,3-dihydroxy-4-methylcyclopentyl)-1H-imidazole-4-carboxamide: a potent protein kinase C-ι inhibitor as a potential prostate carcinoma therapeutic.

Authors:  André H Apostolatos; Christopher A Apostolatos; Wishrawana S Ratnayake; Anthony Neuger; Samer Sansil; Marie Bourgeois; Mildred Acevedo-Duncan
Journal:  Anticancer Drugs       Date:  2019-01       Impact factor: 2.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.